Tenax Therapeutics flags announcement on LEVEL trial data presentation at ESC Congress 2026

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

TENX

0.00
  • Tenax Therapeutics flagged a late-breaking ESC Congress 2026 presentation for Phase 3 LEVEL data on TNX-103 (oral levosimendan).
  • Topline LEVEL results expected in August 2026; database lock and statistical analysis underway.
  • LEVEL tests TNX-103 in PH-HFpEF; enrollment of over 230 patients completed in March 2026; primary endpoint is 6-minute walk distance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020700PRIMZONEFULLFEED9756115) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.